On May 19, 2026, Canaccord Genuity upgraded Progyny (NasdaqGS: PGNY) from a Hold to a Buy rating, projecting a 16.83% upside with a one-year price target averaging $28.75 per share, compared to its latest closing price of $24.60. Forecasts for the stock range from a low of $19.19 to a high of $32.55.
Progyny’s projected annual revenue stands at $1.79 billion, reflecting a 38.58% increase, while the projected annual non-GAAP EPS is $1.50. Institutional ownership has decreased by 10.73%, totaling 89.81 million shares, with 299 funds reporting positions in the company, a drop of 44.83% from the previous quarter.
Major shareholders include Vanguard Portfolio Management with 5.29 million shares (6.76% ownership) and Ameriprise Financial with 2.83 million shares (3.61% ownership), which increased its stake by 19.37% despite reducing its portfolio allocation by 84.45% last quarter.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
